Our translational rheumatology program is powered by exceptional access to RA patient blood and primary synovial tissue. We investigate how immunometabolism drives pathogenic crosstalk between myeloid cells, fibroblast-like synoviocytes (FLS), and endothelial cells in the inflamed joint. By deconstructing these multicellular networks, we identify novel therapeutic targets and predictive biomarkers for RA. Backed by high-impact publications and a proven track record of successful alliances with top-tier pharmaceutical leaders, we are actively seeking new industry partners. We offer robust, human-tissue-based platforms for preclinical therapeutic testing and biomarker discovery to accelerate the development of next-generation RA treatments.